The burgeoning landscape of therapeutic interventions for weight disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 receptor agonist retatrutide. While https://jeanckvi122793.wikistatement.com/5347642/glp_3_retatrutide_a_comparative_analysis